- Home
- EFT vs RXST Comparison
EFT vs RXST Comparison
Compare EFT & RXST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EFT | RXST |
|---|---|---|
| Founded | N/A | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 304.1M | 305.0M |
| IPO Year | 2004 | 2021 |
Fundamental Metrics
Financial Performance| Metric | EFT | RXST |
|---|---|---|
| Price | $10.76 | $7.33 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $11.60 |
| AVG Volume (30 Days) | 130.5K | ★ 666.2K |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $134,479,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $8.69 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.44 | $6.62 |
| 52 Week High | $12.67 | $27.13 |
Technical Indicators
Market Signals| Indicator | EFT | RXST |
|---|---|---|
| Relative Strength Index (RSI) | 31.74 | 39.37 |
| Support Level | $10.62 | $7.34 |
| Resistance Level | $11.45 | $9.11 |
| Average True Range (ATR) | 0.11 | 0.41 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 32.50 | 23.81 |
Price Performance
Historical ComparisonAbout EFT Eaton Vance Floating Rate Income Trust of Beneficial Interest
Eaton Vance Floating-rate Income Trust is a closed-end management investment company. The company's objective is to provide a high level of current income and its secondary objective is capital appreciation.
About RXST RxSight Inc.
RxSight Inc is a commercial-stage medical technology company dedicated to improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture, and sale of light adjustable lenses and related capital equipment.